Where Can You Actually Get Microdose Tirzepatide? 3 Real Options in 2026
"Microdosing" gets attached to every GLP-1 online, but tirzepatide specifically has a much smaller, newer market than semaglutide's. Here's who genuinely sells a named, priced tirzepatide microdose product, what it costs, and where it sits on the drug's real FDA dose ladder.
Only a couple of telehealth platforms sell a real, named tirzepatide microdose product: Fridays is the clearest one, at roughly $198 a month, built for maintenance and wellness rather than new weight loss. The name most people expect to see here, Noom's "Microdose GLP-1Rx," is actually compounded semaglutide only — it doesn't include tirzepatide at all. Beyond that, it's mostly flat-rate titration choices (Mochi Health) or the FDA-approved starting dose itself (Zepbound via LillyDirect), not a distinct microdose SKU.
What you'll actually pay
A genuinely distinct, named compounded tirzepatide-and-blend product on Fridays' own site — separate from its standard weight-loss tirzepatide track. Marketed for "those already stabilized on GLP-1s," energy, and inflammation response, not new weight loss. Some formulation variants (added ingredients like NAD+) have priced closer to $248/mo across Fridays' own pages — ask which exact SKU the quote is for.
See pricesNo separate microdose product. The $199 medication fee is flat at every dose from 2.5mg to 15mg, so a slower, lower-dose titration a prescriber chooses for you costs the same as a standard one — it's the low end of the normal range, not a distinct SKU.
See pricesFDA-approved, brand-name tirzepatide at its own 2.5mg starting dose — the label itself calls this a treatment-initiation dose, "not intended for chronic weight management" alone. Not marketed as a microdose product, but it's the only option here with zero compounded-status question mark. Catch: refill within 45 days to hold this rate — miss that window and the price resets higher, closer to $499–$699/mo.
See pricesWhat actually counts as a microdose of tirzepatide?
There's no FDA definition of a tirzepatide microdose, and that gap is exactly why the term means something different depending on who's selling it. Zepbound and Mounjaro both start every patient at 2.5mg weekly — and the FDA label is explicit that this dose is a treatment-initiation step, not intended for chronic weight management on its own. In one real sense, then, the FDA's own starting dose already is a kind of official microdose: it exists to let the body adjust, not to treat anything long-term.
Where the term gets looser is below that. Compounding pharmacies marketing a tirzepatide "microdose" commonly describe a range well under a milligram a week, sometimes starting near a quarter of a milligram and increasing in small steps under a prescriber's direction. That's provider marketing language, not a clinical guideline — there's no standardized protocol, and it isn't the same thing everywhere you see it advertised.
Where can you actually get microdose tirzepatide — the real, named options
This is the narrower market the brief for this page kept turning up. Search "GLP-1 microdosing" and you'll find three or four familiar names. Search specifically for tirzepatide, and the list shrinks — because several of the platforms that built a microdose brand did it around semaglutide, not tirzepatide.
- Fridays has a genuinely separate "Microdose Tirzepatide" product page, distinct from its standard weight-loss tirzepatide line, blending compounded tirzepatide with ingredients like NAD+ and inositol and positioning it for people already stabilized on a GLP-1 who want to hold their progress and ease side effects — a maintenance and wellness pitch, not a new-weight-loss one.
- Mochi Health doesn't brand a microdose SKU for tirzepatide the way it does for its semaglutide format menu. Its compounded tirzepatide is one flat $199 medication fee at any dose, so a prescriber choosing to keep you lower and slower doesn't change your bill — it's a titration choice inside the normal program, not a separate product.
- Noom's Microdose GLP-1Rx — the program most people land on searching this topic — is built on compounded semaglutide specifically. Tirzepatide and Zepbound are sold through Noom's other programs, not inside the Microdose tier. If tirzepatide is the point, this well-known name isn't actually the answer here.
A couple of smaller platforms — Lemonaid Health and WeightCare among them — also list a compounded tirzepatide microdose product, generally capped around a quarter of a standard maintenance dose. Pricing there is real but less consistently published across sources than the three options above, which is why they're mentioned rather than tabled.
What does tirzepatide microdosing actually cost?
None of the three options above costs dramatically more or less than the others once you annualize them — Fridays' microdose line runs close to $2,376 a year, Mochi's flat-rate program around $3,336, and LillyDirect's starting-dose Zepbound near $3,588 if you refill on schedule. What differs isn't so much the price as what you're buying: a genuinely blended maintenance product at Fridays, a flat-fee titration choice at Mochi, or the one FDA-approved option with no compounded-status caveat at all.
None of these figures include labs, and compounded tirzepatide's legal footing has narrowed since the shortage that once made it common — worth understanding before you enroll anywhere, covered further down. For the fuller field of tirzepatide pricing beyond just microdosing, the cheapest tirzepatide providers stacks up eight options with every hidden fee called out.
The tirzepatide dose ladder, and where a microdose sits on it
Tirzepatide's real titration schedule — the one printed on both the Zepbound and Mounjaro labels — climbs in 2.5mg steps no sooner than every four weeks, up to a 15mg ceiling. A "microdose," in the compounded sense, generally means staying under that ladder's first rung entirely, not just at its early steps.
Not an FDA-recognized dose — this is how compounding-pharmacy marketing typically describes a tirzepatide microdose, and definitions vary by provider.
Treatment-initiation dose only; the label states this isn't intended for chronic weight management on its own — the closest official equivalent to a microdose.
First FDA-recognized maintenance dose
Intermediate titration step
Second FDA-recognized maintenance dose
Intermediate titration step
Maximum FDA-approved dose
For the full ladder, the missed-dose rules, and how price moves as the dose climbs, see the complete tirzepatide dosage chart.
Using tirzepatide as a maintenance microdose once you've already lost the weight
This is where tirzepatide microdosing looks different from the starting-low version most GLP-1 microdosing content assumes. Fridays' own Microdose Tirzepatide product is explicitly built for this: it's aimed at people already stabilized on a GLP-1 who want to hold their progress rather than begin a new titration. That's a genuinely different use case than a first-timer easing in gently.
There's real data starting to support the idea that you don't need to stay on a full weekly maintenance dose forever to keep most of the benefit. A 2025 case-series and modeling study published in the journal Obesity found that spacing doses out to every two weeks, instead of weekly, preserved roughly three-quarters of the weight loss achieved at tirzepatide's 15mg dose and semaglutide's 2.4mg dose. That's a different mechanism than a compounded "microdose" product — it's the same molecule, taken less often, rather than a smaller amount taken on the usual schedule — but it points the same direction: a full maintenance dose, every single week, forever, isn't obviously required once you've reached your goal. Either approach is a conversation for your prescriber, not a switch you flip on your own.
Is there real science behind tirzepatide microdosing, or is this mostly a trend?
Mostly a trend, with one caveat worth naming. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates two separate gut-hormone pathways, and research suggests it's actually somewhat imbalanced toward the GIP receptor rather than acting equally on both. That's a real, distinct mechanism from semaglutide's GLP-1-only action, and it's part of why tirzepatide tends to produce larger average weight loss in trials. What that dual mechanism hasn't done is generate its own body of microdosing evidence: there is no completed clinical trial evaluating tirzepatide at doses below its 2.5mg starting point, for weight loss, inflammation, or anything else.
The trial that established tirzepatide's weight-loss effect, SURMOUNT-1, was built around a clear dose-response relationship at 5mg, 10mg, and 15mg — more drug produced more weight loss, up to the approved ceiling. Deliberately staying well below the starting dose wasn't the protocol that trial tested, and nothing about the GIP/GLP-1 dual mechanism changes that gap. If anti-inflammatory or longevity claims are what drew you to tirzepatide microdosing specifically, treat that as an open, unstudied question — the receptor biology is real, a treatment effect in people is not yet demonstrated.
Are tirzepatide microdosing side effects actually gentler?
Probably somewhat, though not proven at the doses people are calling microdoses. In the trials behind Zepbound's approval, nausea, diarrhea, constipation, and vomiting were all heaviest right after each dose increase and eased as treatment continued — a pattern consistent with a dose-dependent effect, which is the logic behind expecting a gentler ride at a lower dose. But that logic hasn't been tested below 2.5mg in a trial; it's an extrapolation, not a measured result. Our tirzepatide side effects guide has the full incidence numbers at approved doses.
Hair shedding is worth separating out specifically, because it isn't a direct dose effect at all. The telogen effluvium some people report a few months into tirzepatide follows fast weight loss itself, not the drug acting on hair follicles — which is why a slower, lower-dose approach that produces less dramatic weight change would plausibly carry a lower shedding risk, even though no study has measured that directly for a microdose specifically. What doesn't change with dose: tirzepatide's boxed warning about thyroid C-cell tumors, seen in rodent studies, attaches to the molecule itself rather than a specific dose threshold, so a smaller number on the syringe doesn't make that warning irrelevant.
Is this the right starting point for you in perimenopause?
If GI sensitivity already runs high for you — and a lot of women find that perimenopause turns up the volume on nausea and bloating that never used to bother them — a gentler approach to tirzepatide has real appeal, and a slower climb genuinely can mean fewer rough early weeks. It also has a side benefit worth knowing: pacing weight loss more slowly tends to be easier on muscle, which matters more once estrogen decline is already working against your lean mass. We go deeper on that specific tradeoff in GLP-1s and muscle loss in perimenopause.
The honest tradeoff: a lower dose trades some certainty of results for that gentler start, and tirzepatide's own trial data shows a real gap between its lower and higher maintenance doses. If meaningful weight or metabolic change is your main goal, a standard climb toward an approved maintenance dose has the stronger evidence behind it — staying deliberately below that, long-term, is the part still resting more on marketing than on published data.
How to tell a legitimate low-dose tirzepatide protocol from a DIY red flag
The line that matters isn't the number on the dose — it's who's managing it. A legitimate low-dose or maintenance protocol comes from a licensed prescriber, filled through a named 503A compounding pharmacy, with a dose your provider set and can adjust. A red flag looks different: drawing your own reduced dose from a vial without specific instructions, buying an unlabeled "microdosing kit" online, or splitting a Zepbound or Mounjaro pen yourself — these devices are single-use and not designed for repeated draws.
Tirzepatide's compounding landscape has also genuinely narrowed compared to semaglutide's still-shifting one. The FDA declared the tirzepatide shortage resolved in December 2024, and by March 2025 the broad shortage-era compounding pathway had wound down for both 503A pharmacies and larger 503B outsourcing facilities. What remains is a narrower individual-patient pathway — a 503A pharmacy compounding tirzepatide for a specific documented clinical reason the approved version can't meet, not simply because it's cheaper. In April 2026, the FDA went a step further, proposing to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely, citing no ongoing clinical need for bulk compounding. If a seller can't name its compounding pharmacy or explain that clinical-need pathway plainly, that's the moment to walk away rather than adjust anything yourself.
Frequently asked questions
What counts as a microdose of tirzepatide?+–
There's no FDA definition. The closest official equivalent is Zepbound and Mounjaro's own 2.5mg starting dose, which the label itself calls a treatment-initiation dose not meant for chronic weight management alone. Compounding pharmacies marketing a tirzepatide 'microdose' typically mean something smaller still, often well under a milligram a week — that's provider marketing language, not a standardized clinical protocol.
Where can I actually get microdose tirzepatide?+–
Fridays sells the clearest named, priced tirzepatide microdose product, around $198 a month, built for people already stable on a GLP-1 rather than starting fresh. Mochi Health offers tirzepatide at a flat medication price at any dose but doesn't brand a separate microdose SKU. Smaller platforms like Lemonaid Health and WeightCare also list a compounded version, with less consistently published pricing.
Is Noom's microdose program tirzepatide or semaglutide?+–
Semaglutide only. Noom's well-known Microdose GLP-1Rx program is built specifically on compounded semaglutide; tirzepatide and Zepbound are sold through Noom's separate programs, not inside its Microdose tier. If you're specifically searching for tirzepatide, Noom's microdose product isn't actually the answer.
How much does tirzepatide microdosing cost?+–
Fridays' dedicated microdose tirzepatide product runs roughly $198 a month. Mochi Health's flat tirzepatide medication fee is about $199, plus a separate $79 membership, for around $278 all-in at any dose including a lower titration. Brand-name Zepbound's own 2.5mg starting dose runs $299 a month self-pay through LillyDirect.
Can I use a tirzepatide microdose for maintenance after reaching my goal weight?+–
That's the use case Fridays' microdose tirzepatide product is actually built for, and there's emerging data supporting a related idea: a 2025 study found that spacing full tirzepatide doses out to every two weeks, rather than weekly, preserved roughly three-quarters of the weight loss at the 15mg dose. Whether to lower the dose or space it out is a decision to make with your prescriber, not a self-directed switch.
Are tirzepatide microdosing side effects gentler than full-dose tirzepatide?+–
Likely somewhat, since GI side effects like nausea and diarrhea are heaviest right after each dose increase in the trials — but that pattern hasn't been specifically measured below tirzepatide's 2.5mg starting dose. Hair shedding, tied to the pace of weight loss rather than a direct drug effect, would plausibly be less common with a slower, lower-dose approach, though this hasn't been studied directly either.
Is compounded tirzepatide microdosing legal in 2026?+–
Narrowly. After the FDA declared the tirzepatide shortage resolved in December 2024, the broad shortage-era compounding pathway wound down by March 2025 for both 503A and 503B facilities. A 503A pharmacy can still compound tirzepatide for an individual patient with a documented clinical reason the approved version can't meet — not purely because it's cheaper — and the FDA proposed further restricting 503B bulk compounding of tirzepatide in April 2026. Confirm a provider's specific pathway before enrolling.
Does tirzepatide microdosing still carry the same risks as full-dose tirzepatide?+–
The boxed warning about thyroid C-cell tumors, based on rodent studies, attaches to the molecule itself rather than a specific dose level, so it doesn't disappear at a lower dose. Pancreatitis and gallbladder disease are also listed as risks regardless of dose. A smaller amount of the drug doesn't mean a fundamentally different safety profile — it means less clinical data exists at that dose, not fewer risks by default.
Does the dual GIP/GLP-1 mechanism make tirzepatide microdosing different from semaglutide microdosing?+–
Mechanistically, yes — tirzepatide activates both GIP and GLP-1 receptors, with research suggesting it leans somewhat more toward GIP, while semaglutide acts on GLP-1 alone. That's a real, distinct biology. It hasn't translated into its own microdosing evidence base, though: there's no completed clinical trial testing tirzepatide below its 2.5mg starting dose, so the dual mechanism is a scientific fact without a matching microdosing study yet.